Phase I trial of TRXE 009 (Trilexium)

Trial Profile

Phase I trial of TRXE 009 (Trilexium)

Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs TRXE 009 (Primary)
  • Indications Glioma
  • Focus Adverse reactions; First in man
  • Sponsors Kazia Therapeutics
  • Most Recent Events

    • 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
    • 31 Aug 2015 According to a Novogen media release, this trial is expected to begin in 2017.
    • 29 Jul 2015 This trial is expected to begin in 2016/2017 according to a Novogen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top